Form 8-K - Current report:
SEC Accession No. 0001104659-24-101689
Filing Date
2024-09-20
Accepted
2024-09-20 16:05:16
Documents
13
Period of Report
2024-09-16
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2424352d1_8k.htm   iXBRL 8-K 33761
  Complete submission text file 0001104659-24-101689.txt   208924

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btai-20240916.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20240916_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20240916_pre.xml EX-101.PRE 22381
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2424352d1_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 241313404
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)